Introduction

Trafficking of activated T cells into inflammatory sites is a tightly controlled process directed by multiple molecules, in particular adhesion molecules and chemokines (1, 2). Chemokines are small, secreted polypeptides that regulate lymphocyte trafficking by signaling through G protein–coupled seven transmembrane receptors. A flurry of recent in vitro studies has demonstrated that Th1 and Th2 cells express distinct sets of chemokine receptors that might regulate the recruitment and localization of these cells to inflammatory sites (3, 4). CXCR3 and CCR5 have been associated with the Th1 cytokine profile (5, 6), whereas CCR3, CCR4, and CCR8 have been associated with the Th2 phenotype (7–10). Selective recruitment of subsets of CD4+ effector T cells into sites of inflammation may contribute to the development of different pathological conditions.

T lymphocytes are involved in initiating and maintaining airway inflammation and obstruction in asthma (11). Activated CD4+ T cells producing IL-4, IL-5, and IL-13 have been identified in bronchoalveolar lavage and bronchial biopsies of both atopic and nonatopic asthmatic patients (12, 13), and they increase during late asthmatic responses (14–16). Despite the clear evidence for T cell involvement in asthma, the mechanisms of Th2 cell recruitment within the airways remain poorly defined. Recent studies have shown that the CCR3 ligand eotaxin is produced at high levels in human asthma and localizes to the airway epithelium and to inflammatory cells (17). Unlike other eosinophil-attracting chemokines, eotaxin binds to a single receptor, CCR3, that is highly expressed on eosinophils (18, 19). Because CCR3 is also expressed on basophils (20) and on in vitro polarized Th2 cells (7), it has been suggested that the sharing of CCR3 may allow these different cell types to colocalize at sites of eotaxin production. In addition to eotaxin, other chemokines have been shown to preferentially attract Th2 cells in vitro. These include monocyte-derived chemokine and I-309, binding to CCR4 and CCR8, respectively. Although these results suggest that these
chemokines/chemokine receptor axes may be involved in the recruitment of Th2 lymphocytes that could lead to increased airway damage and altered physiology, very limited information is available on the expression and function of these specific receptors during the asthmatic inflammatory response.

In this study we demonstrate that the majority (>90%) of T cells infiltrating the bronchial biopsies of allergen-challenged asthmatics produce IL-4 and express CCR4. CCR8 was expressed on approximately 28% of infiltrating CCR4+ IL-4+ T cells. The two CCR4 ligands, monocyte-derived chemokine (MDC) and thymus and activation-regulated chemokine (TARC), were expressed by airway epithelial cells and their expression was strongly upregulated after allergen challenge. A comparative analysis of T cells infiltrating the bronchi of patients with nonatopic inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD) and pulmonary sarcoidosis revealed that this chemokine/chemokine receptor pattern was specific for atopic asthma. Unlike the T cells infiltrating the asthmatic samples, T cells in both COPD and sarcoidosis produce IFN-γ and express CXCR3, while lacking CCR4 and CCR8 expression. We conclude that CCR4 and, to a lesser extent, CCR8 mark the majority of T cells infiltrating the airway of asthmatic patients after allergen challenge.

Methods

Subjects. Twenty-three subjects entered the study: twelve with atopic asthma, six with COPD, two with pulmonary sarcoidosis, and three healthy controls. All subjects were recruited from the outpatient clinic of the University of Ferrara. At the time of the study, patients with atopic asthma were in a stable condition and free from acute exacerbation of symptoms and from upper respiratory tract infections in the 4 months preceding the study. They had neither received oral/systemic steroids during the last 6 months nor inhaled corticosteroids during the last 6 weeks. Subjects were characterized by medical history, physical examination, and pulmonary function tests, including lung volumes, airway responsiveness to methacholine, or reversibility of airflow limitation, according to standardized techniques (21, 22). Predicted values of forced expiratory volume in 1 second (FEV1) were derived from the European Community for Steel and Coal tables. All the subjects underwent chest x-rays and bronchoscopy. The asthmatic patients were nonsmokers; all but one were males. The diagnosis of asthma was established on clinical and lung function measurements, according to the current international guidelines for diagnosis and treatment of asthma (23). They were all atopic as demonstrated by positive immediate skin prick test to at least one of ten common inhaled allergens. At the time of the study they had mild asthma (23) with normal lung function test and they were treated with inhaled salbutamol as needed. β2-agonists were withheld for at least 12 hours before physiologic testing or allergen challenge. Among the asthmatics, six subjects underwent allergen challenge 24 hours before bronchoscopy. When (in one case) skin prick tests were positive to one or more antigens (skin wheal response >5 mm at 15 minutes), then the allergen selected for inhalation was determined by clinical history. Five subjects received grass pollens (Phleum pratensis, Phlpr) and one received house dust mites (Dermatophagoides pteronyssinus, Derpt). The other six asthmatics had similar skin test responsiveness (five reacted to grass pollens and one to house dust mites). They were exposed to allergen diluent (saline), via nebulizer as described below, 24 hours before bronchoscopy. All subjects were evaluated out of the respective allergen season or after attempts to minimize environmental exposure.

COPD was diagnosed according to the criteria recommended by the European Respiratory Society (24). The six patients (three of them males) were nonatopic and skin prick test–negative and had a history of chronic progressive symptoms, such as breathlessness, cough, and sputum production. They had no history of asthma or other allergic diseases (e.g., rhinitis). They were ex-smokers, and none of them had smoked in the 6 months preceding the study. They had chronic airflow limitation (forced expiratory volume measured after the first second expiration from total lung capacity [FEV1], assessed by spirometry) of less than 80% predicted, with FEV1/vital capacity less than 88% predicted (24). These parameters did not change significantly in the 5 months preceding the study.

Transbronchial biopsies were obtained from two male patients with active pulmonary sarcoidosis. The diagnosis of pulmonary sarcoidosis was based on the clinical presentation, the radiological findings, and the presence of noncaseating epithelioid cell granulomas in biopsy specimens from the lung, in the absence of other known causes of granulomatous disease (25). The two patients were nonsmokers, nonatopic with negative skin prick test, and had not received oral/systemic steroids during the last 6 months. Three normal subjects were accepted as controls, two of them males. They had normal physical examinations, chest x-rays, and lung function tests. The study was approved by the ethical committee of the University Hospital of Ferrara, and all patients gave their informed consent.

Methacholine challenge testing. Nonspecific airway responsiveness was assessed by methacholine inhalation challenge test using a Wright nebulizer. The test was performed by the 2-minute tidal breathing dosing protocol (26). Results were expressed as the provoking concentration of methacholine required to decrease baseline FEV1 by 20% (PC20).

Allergen challenge. Allergen challenge was performed with an antigen that previously elicited a positive skin test response and that correlated with the clinical history of the patient, according to standardized protocols (27). With a De Vilbiss nebulizer, subjects inhaled five times to a total lung capacity, starting with an initial concentration of antigen of 1:10⁶. Spirometry was per-
formed before 5 and 15 minutes after the allergen inhalation challenge. Tenfold increasing concentrations were administered until a fall in FEV₁ of 20% or more was achieved or a concentration of 1:10⁵ was reached. The time of the fall in FEV₁ of 20% or more (early asthmatic response, EAR) was recorded and labeled as time 0. Spirometry was thereafter performed every 15 minutes for the first 2 hours and then hourly for 10 hours. After recovery from EAR, a subsequent fall in FEV₁ greater than 20% base line was considered to be a late asthmatic response (LAR).

**Bronchoscopy, bronchoalveolar lavage, and bronchial biopsies.** Patients exposed to allergen/diluent challenge underwent bronchoscopy 24 hours after the exposure. Bronchoalveolar cells were obtained and analyzed as previously described (28). Three to five endobronchial biopsies were taken through a bronchoscope (Olympus BF type 1T10; Olympus Optical Co., Tokyo, Japan) with sterile forceps (FB 15C; Olympus Co.) from the subcarinae of basal segment bronchi of the right middle lobe (29).

**Transbronchial lung biopsies.** Alligator forceps were used via the bronchoscope to obtain four to five biopsies from the right lower lobe, according to standardized protocols (30).

**Biopsies.** Biopsies were embedded in Tissue-Tek II OCT (Miles Inc., Elkhart, Illinois, USA), frozen within 30 minutes in isopentane, precooled in liquid nitrogen, and processed as previously described (29).

**Antibodies.** Anti–human CD3 mouse mAb was from Novocasta Laboratories Ltd. (Newcastle upon Tyne, United Kingdom); anti–human EG2 mouse mAb was from Amersham Pharmacia Biotech (Cologno Monzese, Italy); anti–human I-309 goat polyclonal antibodies were from R&D Systems Inc. (Minneapolis, Minnesota, USA) and Santa Cruz Biotechnology Inc. (Santa Cruz, California, USA). Rat anti–human CCR3, mouse anti–human CXCR3, goat and mouse anti–human IFN-γ, and goat anti–human IL-4 antibodies were from R&D Systems Inc. Goat anti–human CCR4 antibody was from Santa Cruz Biotechnology Inc. Goat anti–human CCR8 antibody was from Alexis Corp., (San Diego, California, USA). Rabbit anti–human MDC and rabbit anti–human TARC antibodies were from Santa Cruz Biotechnology Inc. All the secondary antibodies, normal sera, avidin-biotin staining kit, peroxidase substrates, and mounting medium for immunohistochemistry were from Vector Laboratories Inc. (Burlingame, California, USA). All the conjugated and unconjugated secondary antibodies for immunofluorescence were from Jackson ImmunoResearch Laboratories Inc. (West Grove, Pennsylvania, USA).

**Immunofluorescence.** Immunofluorescent stainings were carried out on 5-μm-thick cryostat serial sections from each bronchial biopsy displaced in three adjacent series on slides. At least three series were used for each staining. Slides for double immunofluorescent stainings were postfixed with 4% paraformaldehyde in PBS, washed twice in PBS, and blocked first with 0.1% glycine/PBS and then with 15% FBS/PBS (blocking solution). After five washes with wash buffer (0.45 M NaCl, 0.24 M Na₂HPO₄, 0.24 M NaH₂PO₄, 0.3% Triton X-100), the slides were incubated overnight at 4°C with the primary antibodies diluted in blocking buffer in a humidified chamber. The slides were washed again five times with wash buffer, and incubated with the fluorochrome-conjugated (Rhodamine Red-X– or Cy2-conjugated) secondary antibodies diluted in blocking buffer for 1 hour at room temperature. After five washes in wash buffer and two in PBS, the slides were mounted with 90% glycerol/PBS. Negative controls were performed omitting the primary antibody or using an isotype control antibody from the same species. Double labeling with primary antibodies from the same host species (CCR4-CCR8 and CCR4–IL-4) was carried out as recommended by Vector Laboratories Inc. Briefly, after the first single staining, sections were incubated with 15% normal serum to saturate any open antigen-binding site on the Cy2-conjugated secondary antibody, so that binding of the other primary antibody was prevented. The slides were then incubated with an excess of unconjugated Fab secondary antibody to block any nongSpecific binding site, and the other single staining was performed using a Rhodamine Red-X–conjugated secondary antibody. Control stainings using only one primary antibody and both secondary antibodies in every possible combination, and negative controls, omitting one or both primary antibodies, were performed. Once mounted, slides were analyzed with a confocal microscope (MRC-1024; Bio-Rad Laboratories Inc., Hercules, California, USA) equipped with a 15-mW krypton/argon laser emitting at 488 nm and 647 nm, mounted on a Nikon Eclipse E600 microscope (Nikon Instruments SpA, Sesto Fiorentino, Italy). Images were acquired and analyzed with Laser Sharp 3.2 software (Bio-Rad Laboratories Inc.).

**Statistical analysis.** Group data were expressed as means ± SEM, or as median and interquartile range when appropriate. PC₂₀FEV₁, methacholine was expressed as geometric means (geometric standard error of the mean [GSEM]). Logarithmic transformation was done for this value in the statistical analysis. Differences between groups were analyzed using the Kruskal-Wallis test and the Mann-Whitney U test when appropriate. Probability values of P ≤ 0.05 were accepted as significant. With regard to immunofluorescence, at least three replicate measurements were performed by the same observer in nine randomly selected sections. The intraobserver reproducibility was assessed with the coefficient of variation and with the intraclass correlation coefficient. The intraobserver coefficient of variation was 7% and the intraobserver correlation coefficient was 0.71.

**Results.** Th2 lymphocytes represent the predominant infiltrate in bronchial biopsies of atopic asthmatics after allergen challenge. Bronchial biopsies were obtained from six atopic asthmatics 24 hours after allergen challenge, six atopic asthmatics 24 hours after sham challenge
(nonsmokers; one female; mean age 27.6 ± 2.8; mean base-line FEV1 98.5 ± 4.5; PC20FEV1 methacholine 1.3 [0.9] mg/ml), and three healthy controls (one female; mean age 39 ± 6.3). Each of the six asthmatic patients challenged with allergen developed both an EAR and an LAR (nonsmokers; two female; mean age 31.5 ± 2.1; mean base-line FEV1 95.4 ± 5.8; PC20FEV1 methacholine 1.5 [1.1] mg/ml). Bronchoalveolar eosinophils and lymphocytes were significantly increased at 24 hours after allergen challenge (5% [3–5.25%] vs. 1% [0–1.5%]; \( P < 0.01 \)) and (3% [2–6%] vs. 1.5% [0.88–2%]; \( P < 0.05 \)).

Immunohistochemical analysis with anti-CD3, anti-EG2, anti-CD14, anti-CD1a, and anti-tryptase antibodies revealed that only the number of CD3+ cells per square millimeter was significantly increased in the airway mucosa of sham-challenged asthmatics when compared with the nonasthmatic control group (874 [384–1480] vs. 274 [112–440], respectively; \( P \leq 0.005 \)). Upon allergen challenge, the number of subepithelial and intraepithelial CD3+ cells per square millimeter increased significantly (874 [384–1480] vs. 4400 [3870–7060], in sham-challenged and in allergen-challenged asthmatics, respectively; \( P = 0.0022 \)). The number of infiltrating eosinophils was not significantly increased at 24 hours after allergen challenge. At this time, cells staining positive for CD14, CD1a, or tryptase could hardly be detected in any of the tissues analyzed (data not shown). We then analyzed IL-4 and IFN-\( \gamma \) production in infiltrating CD3+ cells by double immunofluorescence. A significant proportion of CD3+ cells in healthy controls (34%) and in sham-challenged asthmatics (40%) produced IL-4, while virtually all the CD3+ cells infiltrating the airway mucosa of allergen-challenged asthmatics were IL-4+ (99.5%) (Figure 1). By contrast, almost no IFN-\( \gamma \)-producing cells were present in the airway mucosa either after sham challenge (1% among all the CD3+ cells) or allergen challenge (0.5% among all the CD3+ cells). Few IFN-\( \gamma \)-producing cells were found in the airway mucosa of healthy controls (11% among all CD3+ cells). These results indicate a predominant airway infiltration of Th2 cells at 24 hours after sham or allergen challenge.

CD3+ cells in bronchial biopsies of allergen-challenged atopic asthmatics express CCR4 and CCR8 but not CCR3. The selective migration of CD4+ cells to inflammation sites is a tightly regulated event depending upon the restricted expression of chemokine receptors on different Th cell subsets. We analyzed, by immunofluorescence, chemokine receptor expression on T cells infiltrating the airway mucosa. Since CCR3 is expressed on in vitro polarized Th2 cells, we first analyzed the tissue distribution of CCR3 expression in allergen-challenged and sham-challenged asthmatics. As shown in Figure 2, CD3+ cells infiltrating the bronchi of allergen-challenged asthmatics did not express CCR3. A few cells expressing CCR3 were only detectable in the airway mucosa of allergen-challenged asthmatics, not in sham-challenged asth-

Figure 1
Cytokine production by T lymphocytes that infiltrate the airway subepithelium of atopic asthmatics. Cryostat sections of a bronchial biopsy from a representative healthy subject (a and d), a representative sham-challenged atopic asthmatic (b and e), and a subject with atopic asthma 24 hours after allergen challenge (e and f). Double immunofluorescent staining with anti-CD3 (green) and anti-IL-4 (red) (a–c) or anti–IFN-\( \gamma \) (red) (d–f) is shown. Arrows point to double-stained cells (yellow). Original magnification: ×40. e, airway epithelium.

Figure 2
Expression of CCR3 by EG2+ cells and airway epithelial cells but not by T cells infiltrating the airway of atopic asthmatics. Cryostat sections of bronchial biopsies from a representative healthy subject (a), a representative sham-challenged atopic asthmatic (b), and a representative subject with atopic asthma 24 hours after allergen challenge (c and d). (a–c) Double immunofluorescent staining with anti-CD3 (green) and anti-CCR3 (red). (d) Double immunofluorescent staining with anti-EG2 (green) and anti-CCR3 (red). Arrows point to double-stained cells (yellow). Original magnification: ×40. e, airway epithelium.
matics or in healthy controls. These cells are likely to be eosinophils, as they coexpress the marker EG2.

The tissue distribution of CCR4 expression in challenged asthmatics versus nonchallenged asthmatics and nonasthmatic controls is shown in Figure 3. Challenged asthmatics showed a significantly higher number of infiltrating CCR4+ Th2 cells per square millimeter compared with sham-challenged asthmatics (3410 [2790–4480] vs. 390 [261–606], respectively; \( P = 0.0022 \)). CCR4 expression was also found on airway epithelial cells in all sections examined both in asthmatics and in controls (see Figures 2, 4, and 6).

T cells expressing CCR8 were also increased in bronchial biopsies from challenged asthmatics as compared with sham-challenged asthmatics (1070 [729–1160] vs. 251 [229–326], respectively; \( P = 0.0022 \)) and were undetectable in healthy controls (Figure 4).

Double immunofluorescence staining with anti-CCR4 and anti-CCR8 antibodies revealed that CCR8+ Th2 cells represent a small subset (28%) of the CCR4+ Th2 population (Figure 5). Our data indicate that 24 hours after allergen challenge, the central airways of atopic asthmatics are infiltrated by Th2 cells that express CCR4, by a smaller population of Th2 cells coexpressing CCR4 and CCR8, and by a few eosinophils expressing CCR3. The maximal decrease in FEV1 during LAR positively correlated with the number of CCR8+ cells (\( r^2 = 0.7361; P = 0.0288 \)) but not of CCR4+ cells (\( r^2 = 0.2732; P = 0.2874 \)) infiltrating the airway mucosa.

MDC and TARC are upregulated in airway epithelium after allergen challenge. On the same biopsies we also examined the expression of MDC and TARC. Both MDC and TARC expression was exclusively detected as a cytoplasmic staining in airway epithelial cells (Figure 6). While we did not observe any difference in the expression of MDC and TARC between healthy controls and sham-challenged asthmatics, their expression on airway epithelial cells was strongly upregulated upon allergen challenge.

Airway CD3+ cells of COPD and pulmonary sarcoidosis express CXCR3 but not CCR4. To evaluate the disease

Figure 3
(a–c) Expression of CCR4 by T cells infiltrating the airway of atopic asthmatics. Cryostat sections of bronchial biopsies from a representative healthy subject (a), a representative sham-challenged atopic asthmatic (b), and a representative subject with atopic asthma 24 hours after allergen challenge (c). Double immunofluorescent staining with anti-CD3 (green) and anti-CCR4 (red) is shown. Arrows point to double-stained cells (yellow). Original magnification: ×40. e, airway epithelium. (d) Individual counts of CCR4-expressing T lymphocytes in the airway subepithelium of atopic asthmatic patients 24 hours after allergen challenge (n = 6) compared with sham-challenged asthmatic subjects (n = 6). The horizontal bars indicate the mean value for each group (419 ± 77 SE, 3560 ± 349 SE in sham-challenged vs. allergen-challenged). The results are expressed as number of cells per square millimeter of subepithelium. Differences between groups were analyzed using the Mann-Whitney test.

Figure 4
(a–c) Expression of CCR8 by T cells infiltrating the airway of atopic asthmatics. Cryostat sections of bronchial biopsies from a representative healthy subject (a), a representative sham-challenged atopic asthmatic (b), and a representative subject with atopic asthma 24 hours after allergen challenge (c). Double immunofluorescent staining with anti-CD3 (green) and anti-CCR8 (red) is shown. Arrows point to double-stained cells (yellow). Original magnification: ×40. e, airway epithelium. (d) Individual counts of CCR8-expressing T lymphocytes in the airway subepithelium of atopic asthmatic patients 24 hours after allergen challenge (n = 6) compared with sham-challenged asthmatic subjects (n = 6). The horizontal bars indicate the mean value for each group (269 ± 25 SE and 984 ± 84 SE in sham-challenged vs. allergen-challenged). The results are expressed as number of cells per square millimeter of subepithelium. Differences between groups were analyzed using the Mann-Whitney test.
The Journal of Clinical Investigation | June 2001 | Volume 107 | Number 11

Coexpression of CCR4 and CCR8 by infiltrating T cells (a and b) and airway epithelial cells (a) of atopic asthmatics. Double immunofluorescent staining with anti-CCR8 (green) and anti-CCR4 (red) on a bronchial biopsy from a representative subject with atopic asthma 24 hours after allergen challenge. Arrows indicate double positive T lymphocytes (yellow). Original magnification: ×40. e, airway epithelium.

Figure 6
Upregulation of MDC and TARC expression on airway epithelial cells of allergen-challenged atopic asthmatics. Cryostat sections of bronchial biopsies from a representative healthy subject (a and d), a representative sham-challenged atopic asthmatic (b and e), and a representative subject with allergic asthma 24 hours after allergen challenge (c and f). Immunofluorescent staining with anti-MDC (a–c) and anti-TARC (d–f) is shown. Original magnification: ×40. e, airway epithelium.
in the initial phase, Th2-type cells. Expression of the CCR4 ligand MDC was found in both dendritic cells and Th2 cells in the skin of AD patients (43). Furthermore, in a mouse model of bacteria-induced fulminant hepatitis, in which Th2 cells are the cause of liver injury after LPS administration, CCR4 was found preferentially expressed in IL-4-producing Th2 cells in vivo. Neutralization of the CCR4 ligand TARC decreased IL-4 production by liver-infiltrating T cells (44).

CCR8 was expressed, after allergen challenge, in approximately 28% of the CCR4/IL-4 double positive airway T cells. To the best of our knowledge this is the first report of CCR8 expression on T cells in a human pathology. The functional role of this T cell population is currently unclear; however, it was recently reported that the deletion of CCR8 attenuates eosinophil accumulation, Th2 cytokine production, and airway hyperresponsiveness in a cockroach allergen model of asthma (45). Interestingly, we found that the number of CCR8+ Th2 cells infiltrating the airway mucosa in challenged asthmatics correlates with the degree of airflow limitation during LAR. The precise mechanism by which CCR8+ Th2 cells are linked to airflow limitation needs to be further investigated both in vitro and in vivo. However, our data suggest that a CCR8 selectively oriented recruitment of Th2 cells into the airways may be involved in the development of airflow limitation after allergen exposure. Surprisingly, we could not find expression of the CCR8-specific ligand I-309 either in the airway mucosa or in epithelial cells. TARC, whose expression is strongly upregulated by airway epithelial cells after allergen challenge, could serve, in vivo, as a ligand for CCR8, although this possibility is debatable (46, 47). An additional possibility is that CCR8+ cells in the airway mucosa respond to a yet unidentified ligand.

In the present study of bronchial biopsies from atopic asthmatics we show that CCR3 is not expressed by airway-infiltrating T cells either before or after allergen challenge. These data are in agreement with previous observations reporting in vivo expression of CCR3 on eosinophils and basophils but not on T cells in the skin of patients with systemic sclerosis (48). Interestingly, in a mouse model of airway hyperresponsiveness, expression of CCR3 was transient and was found only during the initial aeroallergen challenge (37). This may be explained by the observation that while in the mouse CCR3 is upregulated by anti-CD3 stimulation, in human T cells TCR-mediated activation results in downregulation of CCR3 (49).

The comparative analysis of chemokine receptor expression in a different airway disease, such as COPD, clearly indicated that CCR4 expression is specific to asthma. COPD is a disease characterized by the progressive development of airflow limitation associated with a chronic inflammatory process that differs from that seen in asthma, with different mediators, inflammatory effects, and response to treatment (31). In contrast to asthma, T cells in the bronchial mucosa of COPD patients predominantly express IFN-γ and CXCR3 but do not express IL-4 and CCR4. The lack of IL-4 expression by infiltrating T cells confirms the nonatopic nature of COPD, while the expression of CXCR3 is in agreement with a number of published in vitro and in vivo studies in which CXCR3 was consistently found associated with Th1-type responses (5, 6, 50). Similarly, in sarcoidosis, a disease characterized by a typical cell-mediated Th1-type inflammatory response (25, 28, 32–34), we describe that lung T cells express IFN-γ and CXCR3 but not IL-4 and CCR4. These results are consistent with a previous report documenting CXCR3 expression on CD4+ T cells from the bronchoalveolar lavage of sarcoidosis patients (51).

In conclusion, we have demonstrated that upon allergen challenge, CCR4 and to a lesser extent CCR8 are strongly expressed by T cells in airway mucosa, and their ligands TARC and MDC are upregulated in airway epithelial cells of atopic asthmatics. The coexpression of these chemokines and their receptors indicate their involvement in the regulation of lymphocyte recruitment into the asthmatic lung, suggesting that neutralization of this pathway in vivo may modify T cell migration into the airways and the consequent disease progression.
Acknowledgments

We thank Maura Francolini for help with the confocal analysis, Lorenzo Corbetta and Franco Ravenna for performing bronchoscopies, and Daniele D’Ambrosio and Luciano Adorini for the critical reading of this manuscript. The work was supported by grants from the Italian Ministry of University and Research (MURST), Associazione per la Ricerca e la Cura dell’Asma, and Consorzio Ferrararicerche.